Fred Alger Management LLC increased its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 137.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 299,143 shares of the biotechnology company's stock after purchasing an additional 173,227 shares during the quarter. Fred Alger Management LLC owned 0.37% of Codexis worth $1,427,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Summit Investment Advisors Inc. grew its stake in Codexis by 81.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock worth $40,000 after buying an additional 3,783 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new stake in shares of Codexis in the 4th quarter worth about $79,000. China Universal Asset Management Co. Ltd. acquired a new position in Codexis during the 4th quarter valued at about $82,000. Price T Rowe Associates Inc. MD grew its position in Codexis by 38.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,552 shares of the biotechnology company's stock worth $151,000 after purchasing an additional 8,832 shares during the last quarter. Finally, Intech Investment Management LLC grew its position in Codexis by 55.1% in the 4th quarter. Intech Investment Management LLC now owns 33,111 shares of the biotechnology company's stock worth $158,000 after purchasing an additional 11,757 shares during the last quarter. Institutional investors own 78.54% of the company's stock.
Codexis Stock Performance
NASDAQ CDXS traded down $0.09 on Wednesday, hitting $2.47. The stock had a trading volume of 658,833 shares, compared to its average volume of 655,842. Codexis, Inc. has a one year low of $1.90 and a one year high of $6.08. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. The stock has a market cap of $204.63 million, a price-to-earnings ratio of -2.84 and a beta of 2.56. The company's 50-day moving average is $2.45 and its two-hundred day moving average is $3.75.
Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. On average, analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current year.
About Codexis
(
Free Report)
Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
Featured Articles
Before you consider Codexis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Codexis wasn't on the list.
While Codexis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
